Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$129.61M-1.7%-$127.41M+10.6%-$142.46M-6.7%-$133.56M-30.9%-$102.02M-17.2%
$31K+19.2%$26K+4.0%$25K-89.2%$231K-10.5%$258K-8.5%
$24.99M+24.9%$20.01M+68.6%$11.87M+56.2%$7.6M+0.4%$7.57M-19.0%
-$100.01M-5.6%-$94.69M-13.2%-$83.65M-22.4%-$68.33M-41.8%-$48.17M+9.3%
$196K
-$268.33M-8.6%-$247.01M-82.0%-$135.72M-1,145%$12.99M-50.0%$25.98M+18.3%
$360.67M0.0%$360.77M+27.7%$282.61M-25.1%$377.38M+103%$186.07M-0.6%
$5.16M-72.9%$19.05M-62.0%$50.11M-83.8%$308.91M+124%$137.9M-3.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Jade Biosciences, Inc. Common Stock generate?
Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.
What is Jade Biosciences, Inc. Common Stock's free cash flow?
After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.
Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?
Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.